# Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

> **NCT03884998** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Lymphoplasmacytic Lymphoma
- Marginal Zone Lymphoma
- Richter Syndrome

## Interventions

- **DRUG:** Copanlisib
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03884998
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-26
- **Primary completion:** 2026-11-04
- **Final completion:** 2026-11-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884998, "Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03884998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*